Sun Pharmaceutical Industries has reported financials for the third quarter ending December 31, 2012. Net sales / Income from operations were reported at Rs 2852 crores, a growth of 33 per cent over same quarter last year. Branded generic sales in India was at Rs 788 crores, up by 13 per cent over Q3 last year. US finished dosage sales was at $276 million grew by 32 per cent (in $ terms) over Q3 last year. The international formulation sales at $73 million grew by 31 per cent (in $ terms) over same quarter last year. EBITDA was reported at Rs1261 crores seeing a 31 per cent growth compared to Q3 last year. The net profit was at Rs 881 crores which witnessed a growth of 32 per cent over Q3 last year.
Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries said, “All our businesses continue to perform in-line with our expectations. The recent approval of our generic Doxorubicin HCl Liposomal Injection in the US reflects our technological strengths in developing complex products. The acquisition of DUSA and URL’s generic business will further strengthen our presence in the US. Overall, we shall strive to remain focused on execution and building a business with consistent performance.”
EP News Bureau – Mumbai